Interacting Drugs |
Capecitabine vs CYP2C9 Substrates (High risk) |
Security Level |
 |
Mechanism |
CYP2C9 Substrates (High risk): CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates (High risk). |
Management |
Consider therapy modification |
Capecitabine vs CYP2C9 Substrates (High risk)
Post Review about Capecitabine vs CYP2C9 Substrates (High risk) Click here to cancel reply.
Other Interactions of Capecitabine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.